Files

1756286420932035.pdf (232.54 KB)

Document type

Article

Version

Published version

Publication date

2020-06-01

Publication license

cc by-nc (c) Vélez Santamaria et al., 2020
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/171790

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1177/1756286420932035

Abstract

Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.

Subject

Malalties autoimmunitàries, Malalties neuromusculars

Subject (English)

Autoimmune diseases, Neuromuscular diseases

Citation

Collections

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

VÉLEZ SANTAMARIA, Valentina, et al. Eculizumab as a promising treatment in thymoma-associated myasthenia gravis. Therapeutic Advances in Neurological Disorders. 2020. Vol. 13. [consulted: 7 of June of 2026]. Available at: https://hdl.handle.net/2445/171790

Export metadata

JSON - METS

Share record